Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are known to lower the risk of cardiovascular events. However, their potential neuroprotective effects have not been thoroughly investigated. To address this gap, two independent studies examined the association between the use of GLP-1RAs and SGLT2is and the risk of Alzheimer’s disease and related dementias (ADRD) and overall dementia in individuals with type 2 diabetes (T2D).
The first study, involving 396,963 patients, found a lower incidence of ADRD among those treated with GLP-1RAs (hazard ratio [HR]: 0.67) and SGLT2is (HR: 0.57) compared to patients receiving other glucose-lowering medications. 1 The second study, a meta-analysis of 26 clinical trials, reported a significant reduction in dementia risk associated with GLP-1RAs (odds ratio: 0.55), but not with SGLT2is. 2…
